Koukourakis, Michael I <br/><br/>
The effect of trastuzumab/docatexel combination on breast cancer angiogenesis: dichotomus effect predictable by the HIFI alpha/VEGF pre-treatment status?  [electronic resource] 

 -  Anticancer research   
 - 1673-80 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article 
<br/><br/><label>ISSN: </label>0250-7005 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Biopsy<br/>Breast Neoplasms--blood supply<br/>Cell Division--drug effects<br/>Docetaxel<br/>Endothelial Growth Factors--biosynthesis<br/>Female<br/>Humans<br/>Hypoxia-Inducible Factor 1, alpha Subunit<br/>Immunohistochemistry<br/>Intercellular Signaling Peptides and Proteins--biosynthesis<br/>Lymphokines--biosynthesis<br/>Neoplasm Recurrence, Local--blood supply<br/>Neovascularization, Pathologic--drug therapy<br/>Paclitaxel--administration & dosage<br/>Prospective Studies<br/>Receptor, ErbB-2--biosynthesis<br/>Taxoids<br/>Transcription Factors--metabolism<br/>Trastuzumab<br/>Vascular Endothelial Growth Factor A<br/>Vascular Endothelial Growth Factors